Evaluation of Insulin-like Growth Factor Binding Protein 2 (IGFBP2) Efficacy in Classifying Risk Groups in Patients with Non-ST elevation Acute Coronary Syndrome (NSTE-ACS) According to the Reynolds Risk Score

Abstract

Background: Non-ST elevation myocardial infarction (NSTEMI) and unstable angina (UA)as subtypes of non-ST elevation acute coronary syndrome (NSTE-ACS), with NSTEMI characterized by acute myocardial necrosis detectable through cardiac biomarkers. The Reynolds score is a predictive tool that assesses the likelihood of cardiovascular events over the next ten years based on various criteria. Insulin-like Growth Factor Binding Protein 2(IGFBP2), a member of the IGFBP family, interacts with IGFs in the circulatory system to regulate their activity.

Objectives: This study aimed to investigate the relationship between serum IGFBP2 levels and Reynolds scores in patients with NSTE-ACS. with the objective of classifying the risk into three categories: low, medium and high.to assist doctors in evaluating the level of risk based on clinical criteria.

Methods: case-control study included 90 individuals divided into three groups: NSTEMI patients, unstable angina patients, and a control group. The study collected clinical and demographic data, including age, sex, BMI, family history of coronary disease, medical history.

Result: patients with NSTE-ACS showed no significant differences in IGFBP2 levels(p=0.560). among patients categorized into low, medium, and high-risk groups based on the Reynolds score, there was no statistically significant variance in IGFBP2 levels(p=0.750).

Conclusion The study discovered that there were no significant variations in the level of IGFBP2 among the three risk categories defined by the Reynolds Score in individuals with NSTE-ACS. Therefore, it was not possible to classify individuals into Low, medium and high-risk categories using this biomarker